International Journal of Research in Pharmacology & Pharmacotherapeutics (IJRPP)

IJRPP |Vol.15 | Issue 1 | Jan - Mar -2026

www.ijrpp.com

ISSN: 2278-2648

DOI : https://doi.org/10.61096/ijrpp.v15.iss1.2026.33-39

Review

COMPREHENSIVE REVIEW OF HEPATIC FAILURE: PATHOGENESIS, TREATMENT AND FUTURE DIRECTION

Jeenachandran. N[*1], Keerthana VM[1], Malavika. MP[1], Mirza Fathima. P[1], Dr. Anson S. Maroky[1], Dr. G. Babu[2]

[1,2]*Department of pharmacology, Devaki amma memorial college of pharmacy, Pulliparamba, post, Chelembra Malappuram Dt-673634*

[*]Author for Correspondence: Jeena chandran N
Email: jeena.nambayil@gmail.com

Published on: 30.01.2026

Published by:
Futuristic Publications

Abstract

The content examines the vital functions of the liver and the diverse factors, ranging from medications to viral infections, that lead to its failure. It details the biological mechanisms of hepatotoxicity, such as oxidative stress and immune-mediated damage, while identifying key diagnostic biomarkers like transaminases and bilirubin. The overview outlines traditional treatments including corticosteroids and N-acteylcysteine alongside emerging innovative therapies like stem cell regeneration and nanotechnology. Furthermore, it highlights the role of genomic tools such as CRISPR and next generation sequencing in advancing personalized medicine for liver disease. Ultimately the source serves as a comprehensive guide to the pathogenesis, diagnosis, and future medical horizons of hepatic health.

Keywords: Hepatic failure, Metabolism, Transaminases (ALT and AST)

INTRODUCTION

Among the body's most vital organ is the liver. It plays a crucial part in controlling a variety of physiological functions, and its activity is connected to various essential processes, including secretion, storage, and metabolism .The metabolic processes of growth, nutrition provision, energy supply, and reproduction are all facilitated by the liver[1].The liver damage can be caused by biological factors (bacteria, viruses, and parasites), autoimmune diseases (immune hepatitis, primary biliary cirrhosis), and various chemicals, including some medications (high doses of paracetamol (PCM) and antitubercular drugs), toxic substances (carbon tetrachloride (CCl4), thioacetamide (DMN), D galactosamine/ lipopolysaccharide (Gal N/LPS), and, of course, excessive alcohol consumption [2-4].

The current period of hepatology began in the 20th century, driven by rapid advancements in the biological and physical sciences, epidemiology, pathology, microbiological research, immunology, and light and electron

microscopy. Among a plethora of anatomic features studied were the lobules of the human liver and its microcirculatory units[5]. This overview talks about what we know so far about how hepatic failure forms, the therapies that are available now, and innovative ways that focus on personalized therapy and transform the illness.

EPIDEMIOLOGY

1. Age
2. Gender
3. Race
4. Daily dosage
5. Polypharmacy
6. Genetic factors

PATHOGENESIS OF HEPATIC FAILURE

Hepatotoxicity from medications cannot be viewed as a single illness. Hepatotoxicity is caused by a variety of factors, such as disruption of the cell membrane and cell death resulting from covalent binding of the drug to cell proteins, which creates new adducts that serve as immune targets, thereby activating an immunologic response hindrance of cell pathways of medication digestion; strange bile stream resulting from disruption of subcellular actin fibres or interference of trans-port syphons, causing cholestasis and jaundice; in certain cases with minimal cell damage modified cell death (apoptosis), which occurs through the tumor-corruption factor and Fas pathways; and restriction of mitochondrial activity, accumulation of receptive oxygen species, lipid peroxidation, fat aggregation, and cell passing. [6],

Phase I and Phase II reactions are involved in liver metabolism. Phase I encompasses oxidative, reductive, hydroxylation, and de-methylation pathways, mostly through the cytochrome P-450 system, the most significant family of metabolising enzymes found in the liver's endoplasmic reticulum. Phase II reactions, which are typically regarded as detoxification mechanisms, convert phase I reactions' harmful intermediates into non-toxic molecules. Phase II reactions involve the conjugation of compounds with hydrophilic moieties such as glucuronide, sulphate or amino acids and lead to the creation of more water-soluble metabolite which can be excreted easily[7]

- **Drug-induced liver injury**

DILI mimics the causes and symptoms of numerous acute and chronic liver disorders and is essentially a clinical manifestation of an unanticipated detrimental reaction of the liver to medications[8,9] Paracetamol, is one of the most extensively used over-the-counter antipyretic/analgesics. Its toxicity, whether from an unintentional or deliberate overdose, is a persistent worldwide issue that leads to severe cases of hepatotoxicity, acute liver failure, and even irreparable liver damage requiring liver transplantation. While many studies have confirmed that hepatotoxicity from paracetamol overdose is mainly due to glutathione depletion and the subsequent accumulation of harmful metabolites, new studies, including those by Dong [10] and Gajdošik [11] published in this issue, also highlight the role played by other agents and signaling pathways in APAP-induced liver damage

- **Mechanisms of immune-mediated liver injury**

Mechanisms of liver damage caused by the immune system. It is now known that the immune system, rather than the hepatitis virus, causes liver damage in cases of viral hepatitis reaction to the virus[12,13,14,15] Inhibition of hepatitis virus replication is not always connected to liver damage [16] and hepatitis virus can be rapidly removed by anti-viral cytokines [17]. Nonetheless, it appears that there are backup plans for viral removal that depend on the death of both infected and uninfected hepatocytes. The most significant mechanism of liver destruction in viral hepatitis seems to be CD8 T cell-mediated killing, which is promoted principally by Fas, TNFR1 and DR5, rather than by cytolytic granules [18]. However, non-virus-specific T cells may also be attracted to the liver, which aggravate liver damage without contributing to virus control [16,19]

- **Mitochondrial disruption**

Certain chemical substances can interfere with the formation of ATP by blocking the synthesis of nicotinamide adenine dinucleotide and flavum adenine dinucleotide, which has a dual effect on beta-oxidation energy productions[20].

Stages of hepatotoxicity

The degree and intensity of hepatic cell destruction as well as the increase in hepatic biomarkers are used to categorise hepatotoxicity. Liver damage can occur in a number of stages, ranging from minor injury to serious illness, as explained in fig.1.



Figure 1. Stages of liver damage in hepatotoxicity.

Risk factors

Idiosyncrasy, gender, age, alcohol intake, concurrent use of other drugs, smoking, past or underlying liver ailment, and ge- netic and environmental variables are risk factors[21,22]. (Mitochon-drial dysfunction, reduced cellular respiration, or abnormalities in fatty acid oxidation have all been associated to hepatotoxicity[23,24].



Figure 2. Factors which affect the hepatic cells and cause damage of hepatocytes.

DIAGNOSIS

Since the liver performs so many different tasks, there are many different markers that we can use to assess the liver's performance or damage. produced by the cells of this organ. Tests for the liver's excretory function (bilirubin), synthetic function (albumin and prothrombin time), and hepatocyte integrity (transaminases, alkaline phosphatase, GGT) are the three categories of markers.

Enzymes such as transaminases (ALT and AST) are highlighted because their increased liberation is a key indicator of liver dysfunction, though AST elevation can also signal events like a myocardial infarction. Alkaline Phosphatase (ALP) and Gamma-Glutamyl Transferase (GGT) are crucial markers often paired together to

diagnose obstructive or infectious hepatobiliary diseases. Further bilirubin, which is the primary test for evaluating general hepatic metabolic function, and the presence of total plasma proteins, which decrease during acute liver damage. While Lactate Dehydrogenase (LDH) is a general sign of cellular death useful in research, the quantification of ALT, AST, and ALP remains the most critical standard in assessing liver health.[25]

CURRENT TREATMENTS

N-acetylcysteine (NAC)

The use of N-acetylcysteine (NAC) as an effective treatment for acetaminophen (APAP) overdose, explaining that NAC works by binding to the toxic metabolite NAPQI to prevent liver damage. Treatment initiation is often based on the Rumack-Matthews nomogram, with a 150 ug/mL plasma concentration threshold at four hours commonly used in several countries, though some nations, like the U.K., use a lower 100 mg/L threshold..

Corticosteroids

The use of corticosteroids as a treatment modality for drug-induced liver injury (DILI) stemming from various pharmacological agents. Historically, these steroids were applied primarily for immune-mediated drug reactions, such as those seen in anticonvulsant hypersensitivity syndrome or DRESS, although the this notes that corticosteroids do not always improve patient outcomes in severe reactions. Finally, the material addresses immune-type adverse reactions—including hepatitis—associated with the monoclonal antibody ipilimumab, where corticosteroids are frequently required alongside other immunosuppressive drugs to manage the toxicity.

Ursodeoxycholic acid (UDCA)

some case reports propose that ursodeoxycholic acid (UDCA) might be beneficial in shortening injury duration for certain medications, such as amoxicillin-clavulanate, or potentially preventing severe bile duct issues.

Cholestyramine and **Silymarin**

Cholestyramine is discussed for its use in managing pruritus associated with chronic DILI and as a "bile acid washout" strategy, particularly to accelerate the clearance of leflunomide, a drug with a long half-life. The specific dosing OF cholestyramine significantly decreases leflunomide plasma levels over 48 hours [26].

FUTURE PROSPECTIVES

- **Stem cell based therapies**

The discovery of novel, expandable sources that can stimulate liver regeneration has been made possible by stem cell technology. Lately, For the treatment of patients with ACLF, stem cell-based therapies are receiving sufficient attention . By differentiating into various cell types and replacing the damaged tissues, MSCs have enormous potential for growth in the culture system and are essential for tissue regeneration and repair . The range of therapeutic applications, including models of hepatic injury, was expanded by MSCs' ability to home to the site of injury . MSCs repair hepatocyte damage and encourage liver regeneration after homing into the liver and transdifferentiating into hepatocytes in the local micro environment. Phase II clinical trials are currently being conducted to examine the effectiveness of HepaStem cells, a highly sophisticated cell therapy platform made up of human-liver-derived MSCs cultivated in the lab from healthy donors. Hepatic fibrosis in ACLF is caused by an unbalanced synthesis and breakdown of extracellular matrix, which is mediated by portal fibroblasts, bone marrow-derived fibroblasts, and activated hepatic stellate cells. Although the mechanisms of MSCs have been well-described in CLDs, the mechanistic approach of MSCs in the treatment of ACLF is not welldocumented since it was recently introduced as a therapeutic intervention for ACLF and clinical trials are ongoing[27].

- **Nanotechnology in enhancing hepatoprotective efficacy**

By increasing the bioavailability of hepatoprotective phytochemicals, recent developments in nanotechnology have revolutionized the field of medication delivery. Moreover ,nanotechnology increases the therapeutic potential, regulated administration, and targetability of certain phytochemicals. This exact method protects liver cells from harm by maximizing therapeutic potential and minimizing toxicity. Treatment for severe liver illnesses is made possible by breakthroughs in nanotechnology research.The use of nanomaterials in medical products is growing rapidly in the United States, with many submissions focusing on formulations like liposomes for cancer treatment, demonstrating a strong trend toward smaller, more efficient diagnostic and therapeutic tools. The core potential of this technology lies in revolutionizing healthcare through advancements like nano biosensors, nano implants, and improved medical imaging techniques.

- **Genomics in Hepatoprotection**

The hepatoprotective qualities of natural substances have been evaluated through genomic research. One study assessed the effect of alkaline Zamzam water on thethe authenticity of genomic DNA in liver tissues from rodents,

suggesting that it may have protective value for the liver. Zamazam water restores the hepatocytes' natural structure and functional ability. Both the molecular and histological results of the experimental model of liver changes in rodents showed a protective effect. This implies that people with hepatopathies may include Zamazam water in their diets as a hepatoprotective agent.

The Cleome viscosa Linn (Capparaceae) seed extracts show hepatoprotective and antioxidant qualities in vivo. The crude seed extract's capacity to prevent DNA damage was assessed using the DNA nicking assay extract. The plant extract's hepatoprotective properties were investigated in Wister albino rats with liver damage caused by CCL4. Dandelion root extracts were tested in CCl4-induced hepatotoxicity models of Wister albino rats and assessed for genomic DNA integrity. They were also used in clinical settings for liver cleansing. It was discovered that the methyl donor betaine might correct genomic DNA hypomethylation. Adolescent rodents can be protected against non alcoholic fatty liver caused by a high-fat diet by taking betaine supplements.

- **Genomic tools and technologies used in research**
  - ✓ **Next-generation sequencing (NGS)** has transformed life science research and clinical diagnostics, especially detecting genetic variants linked to liver illnesses.
  - ✓ **CRISPR-Cas9**. A potent gene-editing instrument that enables the implementation of precise modifications to DNA ,thereby facilitating therapeutic applications and functional genomic studies.
  - ✓ **RNA Sequencing (RNA-Seq).** Assists in comprehending gene function and regulation by measuring gene expression levels across the entire transcriptome.
  - ✓ **Microarrays.** Enable the analysis of genetic data on a large scale by detecting gene expression patterns and genetic variations. Protein microarrays are a valuable tool in cancer research due to their significant potential, capacity to handle large amounts of data, immediate display of results, increased sensitivity, minimal sample requirement, and improved adaptability.
  - ✓ **Single-Cell Genomics**. Investigates cellular heterogeneity and intricate biological processes by analyzing genetic information at the single-cell level. The advancement of single cell technology has significantly enhanced research on cardiovascular diseases (CVDs)[28].



CONCLUSION

The liver is highly susceptible to damage from drugs, infections, and toxic agents leading to hepatotoxicity through mechanisms such as oxidative stress and immune mediated injury. Key biomarkers aid in early diagnosis and monitoring of liver dysfunction. While conventional treatments remain important, emerging therapies including stem cell regeneration, nanotechnology, and genomic tools offer promising advances toward personalized and effective management of liver diseases. Collectively this overview reinforces the need for continued research and technological innovation to improve diagnostic accuracy, therapeutic efficacy, and long term outcomes in hepatic disease management.

REFERENCES

1] Ahsan MR, Islam KM, Bulbul IJ. Hepatoprotective activity of Methanol Extract of some medicinal plants against carbon tetrachloride-induced hepatotoxicity in rats. *Global J Pharmacol* 2009; 3: 116-122

2]Casafont-Morencos F, Puente A. Pons-Romero F. Infecciones bacterianas y parasitarias del hígado. *Medicine* 2008; 10:563-569

3] Amengual-Guedan MJ, Rodríguez Sánchez JL. Autoinmunidad en las enfermedades del hígado (I). *Inmunologia* 2000; 19:90-102

4] Deshwal N, Sharma AK, Sharma P. Review on hepatoprotective plants. *Int J Pharm Sci Rev Res* 2011; **7**: 15-26

5] Sasse D, Spornitz UM, Maly IP. Liver architecture. Enzyme 1992;46:8-32.

6]Navarro VJ, Senior JR. Drug-related hepatotoxicity. *N Eng J Med* 2006;354:731-9.

7]Kedderis GL. Biochemical basis of hepatocellular injury. Toxicol Pathol.1996;24(1):77-83

8] Suk, K.T.; Kim, D.J. Drug-Induced Liver Injury: Present and Future. Clin. Mol. Hepatol. 2012, 18, 249. [CrossRef] [PubMed]

9] Andrade, R.J.; Aithal, G.P.; Björnsson, E.S.; Kaplowitz, N.; Kullak-Ublick, G.A.; Larrey, D.; Karlsen, T.H. EASL Clinical Practice Guidelines: Drug-Induced Liver Injury. J. Hepatol. 2019, 70, 1222–1261. [CrossRef]

10] Dong, J.; Lim, W.-W.; Shekeran, S.G.; Tan, J.; Lim, S.Y.; Goh, J.W.T.; George, B.L.; Schafer, S.; Cook, S.A.; Widjaja, A.A. Hepatocyte Specific Gp130 Signalling Underlies APAP Induced Liver Injury. Int. J. Mol. Sci. 2022, 23, 7089. [CrossRef] [PubMed]

11] Šrajer Gajdošik, M.; Kovač Peić, A.; Begić, M.; Grbčić, P.; Brilliant, K.E.; Hixson, D.C.; Josić, D. Possible Role of Extracellular Vesicles in Hepatotoxicity of Acetaminophen. Int. J. Mol. Sci. 2022, 23, 8870. [CrossRef] [PubMed]

12] Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089–2094.

13] Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003;362:2095–2100.

14] Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003;38:4–13.

15] Bertoletti A, Naoumov NV. Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol 2003;39:115–124.

16] Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opinion Immunol 2000;12:403–408.

17] Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65–91.

18] Abougergi MS, Gidner SJ, Spady DK, Miller BC, Thiele DL. Fas and TNFR1, but not cytolytic granule-dependent mechanisms, mediate clearance of murine liver adenoviral infection. Hepatology 2004;41:97–105.

19]Bowen DG, Warren A, Davis T, Hoffmann MW, McCaughan GW, De St Groth BF, et al. Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8 T-cell activation by bone marrow-derived cells. Gastroenterology 2002;123:1252–1264.

20] Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol. 1999;15:367-73.

21] Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arch Pathol Lab Med . 2015;139(7):876–887.

22]Kwok R, Tse YK, Wong GH, et al. Systematic review with meta-analysis:non-invasive assessment of non-alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther . 2014;39(3):254–269 .

23]Pessayre D, Fromenty B, Berson A, et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev . 2012;44(1):34–87 .

24] Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol . 2010(196):311–365 PMID:20020267. doi: 10.1007/978- 3- 642- 00663-0_11

25] Delgado Montemayor, Cecilia & Cordero-Pérez, Paula & Salazar-Aranda, Ricardo & Minsky, Naftaly. (2016). Models of hepatoprotective activity assessment. Medicina Universitaria. 17. 10.1016/j.rmu.2015.10.002

26] Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev GastroenterolHepatol.2016;10(4):517-36.doi: 10.1586/17474124.2016.1127756. Epub 2015 Dec 25. PMID: 26633044; PMCID: PMC5074808.

27] Khanam A and Kottilil S (2021) Acute-on-Chronic Liver Failure :Pathophysiological Mechanisms and Management. Front. Med. 8:752875.doi: 10.3389/fmed.2021.752875

28] Jitendra Patel, Harekrishna Roy, Pavan Kuma Chintamaneni, Rukmani Patel, and Raghvendra Bohara *ACS Biomaterials Science & Engineering* 2025; *11* (5), 2528-2549DOI: 10.1021/acsbiomaterials.5c00004